FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068831725> ?p ?o ?g. }

• W2068831725 endingPage "1039" @default.
• W2068831725 startingPage "1032" @default.
• W2068831725 abstract "Study objectives: To evaluate the implication of plasma biomarkers to future cardiovascular events in nondiabetic patients with stable coronary artery disease (CAD). Designs and settings: Prospective, follow-up study at a tertiary referral center. Patients and measurement: Serial plasma biomarkers including high-sensitivity C-reactive protein (hsCRP), homocysteine, soluble adhesion molecules, von Willebrand factor, and lipid profiles were determined before coronary angiograms in a series of nondiabetic CAD patients with stable angina. Among them, 75 consecutive patients who received coronary revascularization (48 coronary interventions and 27 coronary bypass surgeries) later and another 75 age- and gender-matched patients who preferred medical treatment were both enrolled. In patients of each group, major cardiovascular events including cardiac death, nonfatal myocardial infarction, new or repeated coronary revascularization, and hospitalization for unstable angina, stroke, or peripheral artery disease were prospectively followed up for at least 6 months. Results: Patients were followed up to 40 months (median, 18 months). The incidences of major cardiovascular events were similar between the two groups. For patients with medical treatment, plasma levels of hsCRP, homocysteine, low-density lipoprotein, and the ratio of total cholesterol (TC) to high-density lipoprotein cholesterol (HDL-C) were significantly higher in those with cardiovascular events than those without. However, only hsCRP > 0.1 mg/dL (relative risk [RR], 2.78; 95% confidence interval [CI], 1.21 to 6.41; p = 0.016) and TC/HDL-C ratio > 4.8 (RR, 2.42; 95% CI, 1.04 to 5.65; p = 0.041) were independent predictors by multivariable analysis. For patients with revascularization, basal plasma hsCRP levels were higher in those with cardiovascular events than those without (p = 0.04). However, no biochemical markers could predict future major cardiovascular events in these patients. Conclusions: In nondiabetic patients with CAD, basal plasma hsCRP levels were increased with future cardiovascular events regardless of different treatment strategies. Both plasma hsCRP level and TC/HDL-C ratio independently predict future cardiovascular events, confirming the role of plasma biomarkers in clinical risk stratification especially in patients with medical treatment. To evaluate the implication of plasma biomarkers to future cardiovascular events in nondiabetic patients with stable coronary artery disease (CAD). Prospective, follow-up study at a tertiary referral center. Serial plasma biomarkers including high-sensitivity C-reactive protein (hsCRP), homocysteine, soluble adhesion molecules, von Willebrand factor, and lipid profiles were determined before coronary angiograms in a series of nondiabetic CAD patients with stable angina. Among them, 75 consecutive patients who received coronary revascularization (48 coronary interventions and 27 coronary bypass surgeries) later and another 75 age- and gender-matched patients who preferred medical treatment were both enrolled. In patients of each group, major cardiovascular events including cardiac death, nonfatal myocardial infarction, new or repeated coronary revascularization, and hospitalization for unstable angina, stroke, or peripheral artery disease were prospectively followed up for at least 6 months. Patients were followed up to 40 months (median, 18 months). The incidences of major cardiovascular events were similar between the two groups. For patients with medical treatment, plasma levels of hsCRP, homocysteine, low-density lipoprotein, and the ratio of total cholesterol (TC) to high-density lipoprotein cholesterol (HDL-C) were significantly higher in those with cardiovascular events than those without. However, only hsCRP > 0.1 mg/dL (relative risk [RR], 2.78; 95% confidence interval [CI], 1.21 to 6.41; p = 0.016) and TC/HDL-C ratio > 4.8 (RR, 2.42; 95% CI, 1.04 to 5.65; p = 0.041) were independent predictors by multivariable analysis. For patients with revascularization, basal plasma hsCRP levels were higher in those with cardiovascular events than those without (p = 0.04). However, no biochemical markers could predict future major cardiovascular events in these patients. In nondiabetic patients with CAD, basal plasma hsCRP levels were increased with future cardiovascular events regardless of different treatment strategies. Both plasma hsCRP level and TC/HDL-C ratio independently predict future cardiovascular events, confirming the role of plasma biomarkers in clinical risk stratification especially in patients with medical treatment." @default.
• W2068831725 created "2016-06-24" @default.
• W2068831725 creator A5012296972 @default.
• W2068831725 creator A5014845550 @default.
• W2068831725 creator A5035786147 @default.
• W2068831725 creator A5036988297 @default.
• W2068831725 creator A5065824923 @default.
• W2068831725 date "2004-10-01" @default.
• W2068831725 modified "2023-09-26" @default.
• W2068831725 title "Risk Stratification and Prognostic Implication of Plasma Biomarkers in Nondiabetic Patients With Stable Coronary Artery Disease" @default.
• W2068831725 cites W1971005750 @default.
• W2068831725 cites W1997463027 @default.
• W2068831725 cites W2003273574 @default.
• W2068831725 cites W2007174019 @default.
• W2068831725 cites W2010094572 @default.
• W2068831725 cites W2018898909 @default.
• W2068831725 cites W202019503 @default.
• W2068831725 cites W2029037467 @default.
• W2068831725 cites W2037498580 @default.
• W2068831725 cites W2037654598 @default.
• W2068831725 cites W2041661237 @default.
• W2068831725 cites W2048919772 @default.
• W2068831725 cites W2058610272 @default.
• W2068831725 cites W2061252559 @default.
• W2068831725 cites W2067504868 @default.
• W2068831725 cites W2070396041 @default.
• W2068831725 cites W2083507241 @default.
• W2068831725 cites W2085058703 @default.
• W2068831725 cites W2092043066 @default.
• W2068831725 cites W2109946756 @default.
• W2068831725 cites W2114932730 @default.
• W2068831725 cites W2115415893 @default.
• W2068831725 cites W2116404316 @default.
• W2068831725 cites W2117638408 @default.
• W2068831725 cites W2123437217 @default.
• W2068831725 cites W2126131755 @default.
• W2068831725 cites W2128158778 @default.
• W2068831725 cites W2135479614 @default.
• W2068831725 cites W2137570167 @default.
• W2068831725 cites W2140987820 @default.
• W2068831725 cites W2142901936 @default.
• W2068831725 cites W2155693224 @default.
• W2068831725 cites W2315575691 @default.
• W2068831725 cites W2316243284 @default.
• W2068831725 cites W2324841714 @default.
• W2068831725 cites W2328529137 @default.
• W2068831725 cites W2460467964 @default.
• W2068831725 cites W4230870013 @default.
• W2068831725 doi "https://doi.org/10.1378/chest.126.4.1032" @default.
• W2068831725 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15486359" @default.
• W2068831725 hasPublicationYear "2004" @default.
• W2068831725 type Work @default.
• W2068831725 sameAs 2068831725 @default.
• W2068831725 citedByCount "41" @default.
• W2068831725 countsByYear W20688317252012 @default.
• W2068831725 countsByYear W20688317252013 @default.
• W2068831725 countsByYear W20688317252016 @default.
• W2068831725 countsByYear W20688317252017 @default.
• W2068831725 countsByYear W20688317252019 @default.
• W2068831725 countsByYear W20688317252020 @default.
• W2068831725 countsByYear W20688317252021 @default.
• W2068831725 countsByYear W20688317252022 @default.
• W2068831725 countsByYear W20688317252023 @default.
• W2068831725 crossrefType "journal-article" @default.
• W2068831725 hasAuthorship W2068831725A5012296972 @default.
• W2068831725 hasAuthorship W2068831725A5014845550 @default.
• W2068831725 hasAuthorship W2068831725A5035786147 @default.
• W2068831725 hasAuthorship W2068831725A5036988297 @default.
• W2068831725 hasAuthorship W2068831725A5065824923 @default.
• W2068831725 hasConcept C126322002 @default.
• W2068831725 hasConcept C156957248 @default.
• W2068831725 hasConcept C164705383 @default.
• W2068831725 hasConcept C188816634 @default.
• W2068831725 hasConcept C2777090595 @default.
• W2068831725 hasConcept C2777785093 @default.
• W2068831725 hasConcept C2778213512 @default.
• W2068831725 hasConcept C2778425758 @default.
• W2068831725 hasConcept C2779464278 @default.
• W2068831725 hasConcept C500558357 @default.
• W2068831725 hasConcept C71924100 @default.
• W2068831725 hasConceptScore W2068831725C126322002 @default.
• W2068831725 hasConceptScore W2068831725C156957248 @default.
• W2068831725 hasConceptScore W2068831725C164705383 @default.
• W2068831725 hasConceptScore W2068831725C188816634 @default.
• W2068831725 hasConceptScore W2068831725C2777090595 @default.
• W2068831725 hasConceptScore W2068831725C2777785093 @default.
• W2068831725 hasConceptScore W2068831725C2778213512 @default.
• W2068831725 hasConceptScore W2068831725C2778425758 @default.
• W2068831725 hasConceptScore W2068831725C2779464278 @default.
• W2068831725 hasConceptScore W2068831725C500558357 @default.
• W2068831725 hasConceptScore W2068831725C71924100 @default.
• W2068831725 hasIssue "4" @default.
• W2068831725 hasLocation W20688317251 @default.
• W2068831725 hasLocation W20688317252 @default.
• W2068831725 hasOpenAccess W2068831725 @default.
• W2068831725 hasPrimaryLocation W20688317251 @default.
• W2068831725 hasRelatedWork W175811181 @default.
• W2068831725 hasRelatedWork W1991498847 @default.

• next